source
- UniQure tumbles with latest data for Huntington’s gene therapyAnalysts guessed that investors wanted to see stronger durability results at a four-year check-in of the key trial supporting a potential approval of "AMT-130."BioPharma Dive · 22d ago↗ source
- Kodiak Sciences' Phase 3 eye drug data beats Regeneron’s Eylea, shares doubleKodiak Sciences reported that its two experimental treatments for macular degeneration met the primary endpoints in a Phase 3 trial that directly compared them with Regeneron’s Eylea. The data show…